IRUBIS

Bringing life-saving drugs faster to market

by accelerating bioprocess automation



IRUBIS

Biopharma production is slow and expensive

1 10–15 years

From active ingredient to approved medicine. Patients wait — costs keep rising.

2 Manual sampling

Operators take samples by hand and carry them to the lab. Error-prone, slow, blocks automation.

3 Blind flight between measurements

Hours until results are available. A lost batch costs manufacturers millions of euros.

The market demands a solution — Now

+5.5%

Increasing pharma costs per year

Drug costs are growing faster than the economy. Without a solution, rationing looms.


–65%

Cost reduction possible

With automated real-time analytics, the price of antibodies can drop from $150–300/g to $40/g.

IRUBIS

Our answer to the market: Monipa



only 6 kg

Monipa

Replaces traditional offline methods with real-time measurements

Based on mid-infrared light that measures molecular vibrations

No calibration model building, no sampling

Patent approved

Flow Cell


Single-use

GMP-compliant, no cleaning, no cross-contamination.

IRUBIS

Eliminate weeks of reference measurements

Our Software Intelligence



★ Single–point calibration instead of reference runs
★ Delivers actionable data immediately

IRUBIS

Validated by industry leaders

Application in mAb Production

AGC Biologics

Case Study (May, 2025): “Unlocking the Power of Process Analytical Technology (PAT): Elevating Downstream Process Development with Real-Time Data Monitoring.”

Read more here.

Application in mRNA Production



Edita Botonjic-Sehic
Head of Process Analytics
ReciBioPharm

“We’ve had great integration of PAT tools on our production line of which IRUBIS **Monipa** (Mid-IR system) is one of them. IRUBIS Mid-IR **is sensitive to** CQA’s and byproducts in our IVT reaction, therefore enabling chemometric modelling to predict concentration for those components as well as reaction trend such as endpoint.”

Read more here.

IRUBIS

IRUBIS: The most capable provider

Direct comparison with all major competing technologies for antibody purification (UF/DF).

Criterion	Raman	VP-UV	NIR	QCL MIR	IRUBIS MIR
Real-time measurement	++	+++	+++	–	+++
Plug-and-play	-	+++	++	○	+++
Protein	++	+++	++	++	++
Excipients	○	– – –	+	+	+++
Single-use component	○	○	– – –	– – –	+++
Small footprint	○	–	++	++	+++

→ IRUBIS meets all requirements of modern antibody production.

They believed first

Over €6 million already invested — by leading tech and biotech backers in Europe and the US.

High-Tech Gründerfonds

Germany

Germany's largest government-backed early-stage tech investor.

BioProcess360

USA

US specialty fund for bioprocess technologies.

Verve Ventures

Switzerland

Premium VC focused on deep tech and life sciences.

EIC Accelerator

European Union


EU's highest grant funding tier.

Pharma customers in the pipeline: incl. Novo Nordisk · Moderna · AGC Biologics

Customers are paying. Industry leaders are calling. Monipa is moving.

Your investment, our milestones


Clear milestones — from today's status to exit readiness.



IRUBIS

Clear growth trajectory by 2030

From today's pilot business to a profitable growth company — by 2030.



Growth drivers

- **International expansion** (USA, Asia)
- **Filter flow cell launch** (new application area)
- **GMP certification** (access to production)
- **OEM partnerships** (growth lever)

IRUBIS

This is us: Science, Experience, Execution



Lorenz Sykora-Mirle
Co-Founder · CTO · MSc.

★ Inventor of the core tech

Studied applied physics at TU Munich and the Technical University of Denmark.
Developed the low-cost silicon crystals.



Alexander Geißler
Co-Founder · CCO · Dipl.-Kfm.

★ Sales & market strategy

Responsible for market development in Europe and North America.
Building strategic pharma partnerships.



Matthias Eggers
CEO · Dipl.-Kfm.

★ Successful exit: m2p-labs → Beckman Coulter

Previously: Thermo Fisher, Resistell, Genepoint Shanghai.
Joined IRUBIS in 2025 for the international scale-up.

Additionally: 13 employees · engineering, sales, data analytics, quality

The Exit path is clear


Real-time bioprocess monitoring is becoming the new standard —
and industry leaders are buying exactly these technologies.

Potential strategic buyers

- **Danaher (Beckman/Cytiva)**
- **Thermo Fisher Scientific**
- **Repligen**
- **Endress+Hauser**
- **Sartorius**

Trends they are pursuing — exactly where we are positioned

- Real-time process control
- Scale-up in production
- Single-use integration
- Process understanding


Take part in getting modern medicines to patients faster.
Invest in IRUBIS via Companisto
IRUBIS

Legal Notice

Angel Club funding round · GmbH · EN

Note: This document is only non-binding preliminary information that only gives a first impression of the financing option offered. Neither the document nor our statements made in this context can form a sufficient basis for a financing decision. The investor should examine the possible investment on his own responsibility on the basis of his own analyses. This document does not constitute a sales prospectus, a public offer of an investment, an invitation to submit an offer, investment advice or investment brokerage. By providing this information, we do not assume any representations, warranties or other contractual or quasi-contractual obligations, including with respect to the completeness or accuracy of the information reproduced in this document. The prospective return is not guaranteed and may be lower. This document is to be treated confidentially and may not be reproduced in whole or in part, forwarded to third parties or published.

This document has been electronically translated using automated software. The original document is in German. This is a non-binding translation service. Only the German version is relevant.

Legal Notice

Second financing phase · SPV · GmbH · EN

Legal notice: The purchase of this security involves significant risks and may result in the complete loss of the invested assets. The expected return is not guaranteed and may be lower. This document serves to advertise the security. A basic information sheet has been published for this securities offering. This is available at https://www.companisto.com/de/bib.

This document has been electronically translated using automated software. The original document is in German. This is a non-binding translation service. Only the German version is relevant.